An infected catheter often cannot be cured while it is still in place. That is a materials problem, not a drug problem

A patient with an infected central line or urinary catheter is often given antibiotics, does not get better, and improves only once the device is taken out. This is such a familiar clinical pattern that it can look like a failure of the drug. It is not. It is a consequence of what happens on the surface of anything left inside a human body for more than a few days, and it is one of the clearest cases in medicine where the answer lies in materials science rather than pharmacology.

Every indwelling device — catheter, central line, breathing tube, prosthetic joint, heart valve — is a surface that the body did not put there. Bacteria are very good at colonising surfaces. What they build once they arrive is the reason this is hard.

Why a biofilm is not just a lot of bacteria

Within minutes of a device entering the body, host proteins adsorb onto it and form a conditioning film. Bacteria then attach to that layer, not usually to the bare material, and having attached they begin to behave differently: they secrete a matrix of polysaccharides, proteins and extracellular DNA that binds the community together and to the surface. That structure is a biofilm.

Its defining property is that the organisms inside it become enormously harder to kill — commonly cited as hundreds to a thousand times less susceptible than the same organisms swimming freely. The crucial point, and the one most often garbled, is that this is not antibiotic resistance in the genetic sense. The bacteria have not acquired resistance genes. Their tolerance is phenotypic, produced by the situation they are in:

• The matrix slows drug penetration and binds some drugs outright.
• Nutrients and oxygen are depleted deep inside, so cells there grow slowly — and most antibiotics act on processes that only happen in actively growing cells.
• A subpopulation enters a dormant persister state that is essentially untouchable by antibiotics and repopulates the biofilm once the drug is withdrawn.

Take those bacteria out of the biofilm and test them in a laboratory broth, and they will look perfectly susceptible. The sensitivity report will say the drug should work. In the patient, it does not.

This explains the clinical rule that surprises families: an established device infection frequently cannot be cured while the device remains, and removal or replacement is part of the treatment rather than an admission of defeat. It also explains why prevention is worth so much more than cure here — which is where coatings come in.

Two opposite jobs on the same patient

Here is the structural point that makes device coatings more interesting than surface coatings generally.

Sometimes you want cells to stick, and sometimes you want them not to, and a single patient may have both on the same day.

An orthopaedic implant or dental fixture needs bone to grow onto it and lock it in place. Hydroxyapatite coatings — the mineral phase of bone itself, applied to a metal stem — exist to encourage exactly that, and osseointegration is the whole objective. A coating here is an invitation.

A urinary catheter or a central line wants the opposite: nothing should attach at all, neither protein nor cell. The strategy there is antifouling — surfaces that resist the initial protein adsorption that everything else is built on. Polyethylene glycol layers and zwitterionic polymer brushes hold a tightly bound water layer at the surface that proteins cannot displace, so the conditioning film never properly forms. It is a genuinely elegant idea: rather than killing anything, remove the first rung of the ladder.

And then there is the third approach, the one people expect: release. Silver, antiseptics such as chlorhexidine, or antibiotics loaded into or onto the device to kill what arrives.

There is also a large and quietly important category that has nothing to do with infection at all. Hydrophilic lubricious coatings on guidewires and catheters make them slippery when wet, which is what allows a wire to be steered through a blood vessel without injuring it. These are a real success — and they carry their own failure mode, since coating material that separates or flakes off inside the vasculature has been a recognised device-safety concern, prompting regulatory attention. A coating on a device is never only a coating; it is a component that can fail on its own terms.

What the evidence actually shows

This is where the subject becomes genuinely instructive, because the gap between laboratory performance and clinical benefit is wide, well documented, and rarely mentioned in product literature.

Urinary catheters. Silver-alloy coated catheters reduce bacterial colonisation impressively in the laboratory. A large multicentre randomised trial in the UK, published in 2012, compared silver-alloy and nitrofural-impregnated catheters against standard ones for short-term use, and found that silver-alloy catheters did not produce a clinically meaningful reduction in symptomatic urinary tract infection. The nitrofural catheters showed a small effect that the investigators did not regard as clinically worthwhile at the cost. That result did not overturn the science of silver; it demonstrated that reducing colonisation on a surface and reducing symptomatic infection in a patient are different endpoints, and that only the second one matters.

Central venous catheters. The evidence here is more favourable. Catheters impregnated with chlorhexidine and silver sulfadiazine, or with minocycline and rifampin, do reduce catheter colonisation, and meta-analyses have found reductions in catheter-related bloodstream infection — with the effect on colonisation more consistent than the effect on bloodstream infection, and benefit concentrated in higher-risk settings and longer dwell times. Guidelines generally position them as an option where infection rates remain high despite good insertion and maintenance practice, rather than as a routine default.

Endotracheal tubes. A large randomised trial of silver-coated endotracheal tubes found a reduction in the incidence of ventilator-associated pneumonia, but no significant difference in mortality, duration of ventilation or length of stay. That is a scientifically real result whose clinical value remains debated, and it is a good illustration of why an infection-rate endpoint is not automatically a patient-outcome endpoint.

Coronary stents. This is the field's clearest success, and it is worth noting that it is not an infection story at all. Bare-metal stents suffered from restenosis — the vessel re-narrowing as tissue grew back. Drug-eluting stents, which release an antiproliferative drug from a polymer coating over weeks, substantially reduced that, and are now standard. The story also carries its own correction: early-generation devices raised concerns about late stent thrombosis and required prolonged dual antiplatelet therapy, and later generations with improved polymers and thinner struts were developed in response. A coating that works is still a coating with consequences.

The pattern across all of it is consistent. Coatings reliably reduce what happens on the surface. Whether that translates into a patient being better off depends on the device, the setting and the duration, and it has to be demonstrated separately every time.

The thing that works better than any coating

Any honest article on this subject has to say the following clearly, because it is the finding with the largest effect size in the entire field.

The interventions that have most reduced device-associated infection are not materials at all. They are insertion and maintenance practice: full sterile barrier precautions, chlorhexidine skin preparation, avoiding the femoral site for central lines, hand hygiene, closed drainage systems for urinary catheters, daily review of whether the device is still needed, and prompt removal when it is not. Bundles of these measures have produced large, reproducible reductions in bloodstream and urinary infections across many health systems, at low cost.

Coatings are an adjunct to that, and they are most defensible where good practice is already in place and rates remain stubborn. A coated device used to compensate for weak insertion technique is a expensive way of not fixing the problem. This matters particularly in India, where the surveillance data compiled through ICMR's hospital infection network has shown device-associated infection rates that vary widely between institutions — a spread that is largely about process rather than product.

A coating inside the body is a regulated device

One structural difference from every other coating this series has covered: a surface treatment on a wall is a product, but a coating on an implant is part of a medical device, and it is regulated as one.

In India, medical devices fall under the Medical Devices Rules, 2017, administered by CDSCO, with a risk-based classification from Class A through Class D. An implantable device with an active coating sits at the high-risk end. What that means practically is that the coating cannot be evaluated on its own — it is assessed as part of the finished device, through biocompatibility testing under the ISO 10993 series, sterilisation validation, and clinical evidence appropriate to its risk class. A coating that performs beautifully in a laboratory and has no device dossier behind it is not a medical product; it is a laboratory result.

This is also the reason a general-purpose antimicrobial surface coating, however good, cannot simply be applied to a device. The qualification is not transferable, and the same principle appeared with food contact: a material qualified for one contact scenario has not thereby been qualified for another. Smart Warrior Coatings, part of Reinste Nano Ventures — which, in the interest of disclosure, belongs to the same group as this publication — sells surface and environmental hygiene coatings, and the distinction between those and clinical device coatings is exactly the one worth keeping clear: cleaning a bed rail and coating an implant are different regulatory universes, and a supplier who blurs them is telling you something about themselves.

Why it matters for students and researchers

Biomaterials is one of the better fields for an Indian research student, because it is genuinely interdisciplinary and much of the interesting work does not require exotic equipment.

The central open problem is that biofilm prevention has no general solution. Antifouling surfaces work well in clean laboratory conditions and degrade in the protein-rich, mechanically active reality of the body. Release coatings exhaust their reservoir on a timescale shorter than many devices stay in. And there is a legitimate concern that sub-lethal antimicrobial release at a device surface creates selection pressure, which is one reason non-releasing strategies attract so much interest.

The active directions are worth knowing. Zwitterionic and polymer-brush surfaces that resist protein adsorption without killing anything. Stimulus-responsive coatings that release an agent only when they detect the local pH change or enzyme activity that signals infection, rather than continuously. Nitric oxide-releasing surfaces, which exploit an endogenous antimicrobial molecule with a very short half-life. And anti-adhesive topography — surfaces textured at the micrometre scale to physically discourage attachment, an approach directly descended from studying shark skin, and one that has the appealing property of presenting no chemical for an organism to adapt to.

Two practical gaps sit alongside these. Laboratory biofilm models correlate poorly with clinical outcomes, and better predictive models are unglamorous, valuable work. And India-specific device-infection epidemiology — which organisms, which resistance patterns, in which unit types — is thinner than a country with this hospital volume warrants, while being answerable with careful data collection rather than expensive instruments.

Frequently asked questions

Why do doctors remove a device instead of just treating the infection?

Because the biofilm on the device is a reservoir that antibiotics often cannot clear at achievable concentrations, so the infection returns as soon as the drug stops. Removing the colonised surface removes the source. Decisions about any individual device are clinical judgements that depend on the device, the organism and the patient, and are for the treating team — but the underlying reason is a materials one rather than a failure of the drug.

If the lab report says the bacteria are sensitive, why is the antibiotic not working?

Because susceptibility testing is done on free-floating bacteria in broth, which is a different situation from the same organisms embedded in a biofilm matrix on a plastic surface, growing slowly with poor drug penetration and a dormant subpopulation. The report is accurate about the organism and does not describe the environment it is living in.

Are antimicrobial-coated catheters worth the extra cost?

It depends on which device and which setting, and the honest answer varies. For central venous catheters the evidence supports a reduction in colonisation and some reduction in bloodstream infection, and guidelines typically suggest them where rates remain high despite good practice. For short-term urinary catheters, a large randomised trial found silver-alloy coating did not deliver a clinically meaningful reduction in symptomatic infection. That is a purchasing decision for a hospital's infection control committee based on its own rates, not a general rule.

Is silver on a device the same as silver in a surface spray?

The chemistry overlaps; the qualification does not. A device coating must be assessed for biocompatibility, sterilisation compatibility and clinical performance as part of a regulated device, under a framework that a general surface product is not evaluated against. Nothing about a coating working on a countertop implies anything about its suitability inside a body.

What actually reduces hospital infections the most?

Process, by a wide margin. Sterile insertion technique, chlorhexidine skin preparation, hand hygiene, closed drainage, daily review of whether the line or catheter is still needed, and removing it the moment it is not. These measures have produced the largest and most reproducible reductions anywhere in the literature, and they cost far less than coated devices. Coatings are worth considering after those are reliably in place, not instead of them.